It is provided a method for evaluating damage of an organ tissue, in particular ischemic damage/injury of an organ tissue. The method includes the steps of measuring the concentration of at least one marker molecule in the perfusate of the organ tissue, where the measured concentration of the at least one marker molecule in the perfusate is used in at least one computer based prediction algorithm for generating at least one success score. The success score has been previously defined based on at least one parameter value of at least one pre-defined parameter. The at least one parameter value is determined after a transplantation of the organ tissue; and wherein based on the at least one success score at least one signal and/or at least one set of data is generated for facilitating the decision, if the organ tissue is suitable for transplantation or not.

Predicting recurrence of hepatocellular carcinoma (HCC) after liver transplantation. The disclosure indeed discloses a set of biomarkers present in a serum sample taken from a HCC patient before liver transplantation, which can be used to assess recurrence of HCC after liver transplantation. More specifically, the disclosure discloses a process to predict the recurrence of HCC after liver transplantation via determining the amount of at least four specific N-glycans in a serum sample.

By using a fully phenotyped cohort of kidney transplant recipients (KTRs), inventors have clearly established the clinical conditions that should be considered when using urinary chemokine levels to noninvasively identify patients at risk of acute rejection (AR). They have developed and validated (in two external validation cohorts) a multiparametric model that predicts individual risk of AR with high accuracy. Accordingly, the invention relates to a method for calculating a probability (p) to have a risk of an acute rejection (AR) in a kidney transplant recipient by using the following equation: (I)

[00001]$\begin{array}{cc}p=\frac{1}{\begin{array}{c}1+\exp (-(\mathrm{\beta 0}+\mathrm{\beta 1}x1+\mathrm{\beta 2}x2+\mathrm{\beta 3}x3+\mathrm{\beta 4}x4+\\ \mathrm{\beta 5}x5+\mathrm{\beta 6}x6+\mathrm{\beta 7}x7+\mathrm{\beta 8}x8))\end{array}}.& \left(1\right)\end{array}$

The invention provides a method for identifying a subject suitable for receiving a lung transplant, the method comprising: subjecting a sample to mass spectrometry analysis (in the negative ion mode or positive ion mode; preferably in the positive ion mode) and generating a mass spectrum output; wherein said sample is an isolated sample obtained from a subject that is a candidate for receiving a lung transplant; detecting one or more peak set in said mass spectrum output; wherein the presence of said one or more peak set indicates that the subject is not a suitable candidate for receiving a lung transplant; or wherein the absence of said one or more peak set indicates that the subject is a suitable candidate for receiving a lung transplant. The invention relies on the detection of peak sets specific to the membrane of pathogens, in particular mycobacteria.

Provided are a method of diagnosing the onset of acute rejection, the method including the step of correlating expression levels of one or more miRNAs selected from the group consisting of 8 kinds of miRNAs including miR-4488, miR-4532, miR-146a-5p, miR-21-5p, miR-373-3p, miR-31-5p, miR-223-3p, and miR-210-3p, and a combination thereof with the onset of acute rejection in kidney transplant patients, a composition for diagnosing acute rejection, the composition including an agent capable of measuring the expression level of each of the miRNAs, a kit for diagnosing acute rejection, the kit including the composition, and a method of treating acute rejection, the method including the step of treating acute rejection, when the onset of acute rejection is identified by the above diagnostic method. Since miR-4488, miR-4532, miR-146a-5p, miR-21-5p, miR-373-3p, miR-31-5p, miR-223-3p, and miR-210-3p according to the present invention exist in high levels in the urine of a patient with acute kidney transplant rejection, they may be used to easily diagnose the onset of acute kidney transplant rejection, thereby being used in the effective treatment of acute rejection after kidney transplantation.

In vitro methods for detecting and measuring an antigen-specific regulatory T cell response are described. In particular, there is provided, for example, a method of detecting a change in surface expression of particular T cell markers in T cells obtained from the subject as a way to detect induced immune suppression in response to exposure to a particular antigen or plurality of antigens.

A method of classifying a lung graft subjected to normothermic ex vivo lung perfusion (EVLP), during perfusion and/or after perfusion, the method comprising: a) collecting a test sample from the lung graft; b) measuring a polypeptide level of a negative transplant predictor gene product selected from CCG predictor gene products M-CSF, IL-8 SCGF-beta, GRO-alpha, G-CSF, MIP-1 alpha, and/or MIP-1beta, endothelin predictor gene products endothelin 1 (ET-1) and/or big ET-1, and/or apoptosis predictor gene products cytokeratin 18 (CK-18), caspase 3 and/or HMGB-1 in the sample and/or determining a metabolite profile of the sample for lung grafts that are from donors where the death was due to cardiac death (DCD); c) identifying the graft as a good candidate for transplant or a poor candidate for transplant wherein an increased polypeptide level of one or more negative transplant outcome predictor gene products compared to an outcome control or a reference metabolic profile is indicative the graft is a poor candidate for transplant.

Provided herein is the use of measurements of cell-free DNA, protein, and/or metabolite found in biofluid (e.g., urine) for identifying and treating organ injury. Provided herein are methods and compositions for monitoring, detecting, quantifying, and treating kidney injury in subjects suffering from or suspected of having an altered renal status by measuring amounts of cfDNA and one or more other markers, such as inflammation markers, apoptosis markers, protein, and DNA methylation.

The present invention provides methods utilizing changes in CD4+CD57+ T cells levels for determining the susceptibility of a transplant patient or patient in need thereof to costimulation blockade resistant rejection. These methods are useful for identifying effective drug regimens for the treatment of immune disorders associated with graft transplantation and/or maintenance of a transplant.

New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.